Edrophonium
(Tensilon, Reversol, Enlon)
|
Category:
Description:
Indications:
-
Curare
antidote
-
Diagnosis
of myasthenia gravis
-
Differentiate
between cholinergic crisis and myasthenia gravis crisis
-
Evaluation
of treatment requirements in myasthenia gravis
Contraindications:
Precautions:
-
Pregnancy
category C; ionized at physiologic pH, not expected to cross placental
barrier or excreted in breast milk
-
May
cause premature labor
-
Seizure
disorders, bronchial asthma, recent coronary occlusion,
hyperthyroidism
-
Dysrhythmias,
peptic ulcer, megacolon, poor GI motility, bradycardia, hypotension
Adverse
Reactions (Side Effects):
-
CNS:
dizziness, drowsiness, headache, incoordination, seizures, sweating,
paralysis, weakness, loss of consciousness
-
CV:
AV block, bradycardia, cardiac arrest, dysrhythmias, , syncope,
hypotension, tachycardia
-
EENT:
blurred vision, lacrimation, miosis, visual changes
-
GI:
cramps, diarrhea, dysphagia, increased peristalsis, increased salivary
and gastric secretions, nausea, vomiting
-
GU:
Frequency, incontinence, urgency
-
MS:
arthralgia, fasciculations, muscle cramps and spasms, weakness
-
RESP:
bronchospasm, dyspnea, laryngospasm, respiratory arrest, respiratory
depression, increased tracheobronchial secretions
-
SKIN:
rash, urticaria
|
Dosage:
Administered
IV/IM
-
Adult:
-
Diagnosis
of myasthenia gravis:
-
IV
1-2mg over 15-30 seconds, then
8mg if no response
-
IM
10mg; if cholinergic reaction occurs, retest after ½ hour
with 2mg IM
-
Evaluation
of treatment requirements in myasthenia gravis:
-
IV 1-2mg 1 hour after PO dose of anticholinesterase
-
if strength improves, an increase in neostigmine or
pyridostigmine is indicated
-
Differentiation
of myasthenic crisis from cholinergic crisis:
-
IV 1mg, if no response in 1 minute, may repeat
-
myasthenic crisis clear improvement in
respiration
-
cholinergic crisis increased oropharyngeal
secretions and further weakening of respiratory muscles (intubation
and controlled respiration may be required)
-
Curare
antagonist:
-
Child:
|
Source:
Operational Medicine 2001, Health
Care in Military Settings, NAVMED P-5139, May 1, 2001, Bureau
of Medicine and Surgery, Department of the Navy, 2300 E Street NW, Washington,
D.C., 20372-5300
|